Table 2.

Proportion of patients with a clinically meaningful response, based on funding source: Only studies with clear public or industry funding were analyzed. Those with unclear funding sources were not included in the analysis.

TREATMENT TYPERCTSINDUSTRY FUNDINGINTERVENTION EVENT RATE, % (N/N)CONTROL EVENT RATE, % (N/N)RISK RATIO (95% CI)NNTP VALUE*
Exercise0Industry fundingNANANANANA
10Clearly publicly funded47 (332/703)22 (136/634)2.38 (1.78–3.18)4
Intra-articular corticosteroids3Industry funding50 (129/257)44 (68/155)1.15 (0.85–1.55)NSS.05
3Clearly publicly funded49 (46/94)17 (14/82)2.66 (1.22–5.77)4
SNRIs (duloxetine only)6Industry funding64 (655/1030)43 (443/1030)1.53 (1.25–1.87)5NA
0Clearly publicly fundedNANANANA
NSAIDs (oral)39Industry funding57 (11 785/20 810)39 (2560/6518)1.42 (1.34–1.50)6.008
1Clearly publicly funded67 (214/318)57 (178/313)1.18 (1.05–1.34)10
Glucosamine6Industry funding41 (176/425)25 (105/423)1.62 (1.28–2.05)7.006
3Clearly publicly funded52 (208/399)51 (201/396)0.99 (0.76–1.28)NSS
NSAIDs (topical)14Industry funding56 (1594/2847)48 (1354/2808)1.19 (1.09–1.31)13NA
0Clearly publicly fundedNANANANA
Chondroitin8Industry funding54 (505/932)41 (375/914)1.30 (1.14–1.49)8.10
1Clearly publicly funded64 (202/318)57 (178/313)1.12 (0.98–1.27)NSS
Viscosupplementation23Industry funding54 (1502/2805)45 (1137/2555)1.20 (1.10–1.32)12.72
1Clearly publicly funded36 (30/84)32 (27/84)1.11 (0.73–1.70)NSS
Opioids (oral)14Industry funding46 (1740/3743)43 (992/2293)1.17 (1.02–1.34)32NA
0Clearly publicly fundedNANANANA
Acetaminophen2Industry funding47 (240/513)43 (204/478)1.17 (0.83–1.64)NSSNA
0Clearly publicly fundedNANANANA
  • NA—not applicable, NNT—number needed to treat, NSAID—nonsteroidal anti-inflammatory drug, NSS—not statistically significant, RCT—randomized controlled trial, SNRI—serotonin-norepinephrine reuptake inhibitor.

  • * P value for testing between subgroup differences.

  • Not applicable, as one subgroup was not present.